Thus, gut-secreted HSP70 and GRP78 are molecular targets for the treatment of T2D and NAFLD, whose inhibition shows a similarly high efficacy to that of metabolic surgery. The gene discussed is HSPA5; the disease is type 2 diabetes mellitus.